Hallucinogens

Pharmacology and Therapeutics

Volumn 101, Issue 2, 2004, Pages 131-181

  Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

5 HT2A receptors; Hallucinogen; Prefrontal cortex

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 2 AMINO 5 PHOSPHONOVALERIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; BENZODIAZEPINE DERIVATIVE; CORTICOSTERONE; CORTICOTROPIN; EGLUMETAD; FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; KETANSERIN; LYSERGIDE; MESCALINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N,N DIMETHYLTRYPTAMINE; NEUROTRANSMITTER; PHENETHYLAMINE DERIVATIVE; PIRENPERONE; PROLACTIN; PSILOCYBINE; PSYCHEDELIC AGENT; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN RECEPTOR; SPIPERONE; TRYPTAMINE DERIVATIVE; UNINDEXED DRUG;

ACUTE PSYCHOSIS; ALCOHOLISM; ANXIETY DISORDER; BRAIN; BRAIN CORTEX; COGNITION; CORRELATION ANALYSIS; DRUG METABOLISM; GENE EXPRESSION; HUMAN; IMAGING; IN VIVO STUDY; INTOXICATION; MENTAL DISEASE; NEUROANATOMY; NEUROSCIENCE; NEUROTRANSMISSION; NONHUMAN; PERSISTING PERCEPTION DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; PYRAMIDAL NERVE CELL; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYMPTOMATOLOGY; THALAMOCORTICAL TRACT; THALAMUS; WORKING MEMORY;

EID: 0842324481     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2003.11.002     Document Type: Review

References (520)

1. 2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology. 20:1999;92-96.
2. Abraham H.D., Aldridge A.M., Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology. 14:1996;285-298.
3. Acuna-Castillo C., Villalobos C., Moya P.R., Saez P., Cassels B.K., Huidobro-Toro J.P. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br J Pharmacol. 136:2002;510-519.
4. Aghajanian G.K. Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli. Brain Res. 186:1980;492-498.
5. Aghajanian G.K., Bing O.H.L. Persistence of lysergic acid diethylamide in the plasma of human subjects. Clin Pharmacol Ther. 5:1964;611-614.
6. Aghajanian G.K., Haigler H.J. Hallucinogenic indoleamines: preferential action upon presynaptic serotonin receptors. Psychopharmacol Commun. 1:1975;619-629.
7. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology. 36:1997;589-599.
8. 2A receptors enhance asynchronous excitatory transmission in pyramidal cells (layer V) of prefrontal cortex. Soc Neurosci Abstr. 24:1998;1366.
9. Aghajanian G.K., Marek G.J. Serotonin and hallucinogens. Neuropsychopharmacology. 21:1999;16S-23S.
10. 2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. 825:1999;161-171.
11. Aghajanian G.K., Marek G.J. Serotonin-glutamate interactions: a new target for antipsychotic drugs. Neuropsychopharmacology. 21:1999;S122-S133.
12. Aghajanian G.K., Foote W.E., Sheard M.H. Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science. 161:1968;706-708.
13. Aghajanian G.K., Foote W.E., Sheard M.H. Action of psychotogenic drugs on single midbrain raphe neurons. J Pharmacol Exp Ther. 171:1970;178-187.
14. Aghajanian G.K., Haigler H.J., Bloom F.E. Lysergic acid diethylamide and serotonin: direct actions on serotonin-containing neurons in rat brain. Life Sci. 11:1972;615-622.
15. Agnati L.F., Zoli M., Stromberg I., Fuxe K. Intercellular communication in the brain: wiring versus volume transmission. Neuroscience. 69:1995;711-726.
16. Ahn H.S., Makman M.H. Interaction of LSD and other hallucinogens with dopamine-sensitive adenylate cyclase in primate brain: regional differences. Brain Res. 162:1979;77-88.
17. Akin D., Onaran H.O., Gurdal H. Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. Br J Pharmacol. 136:2002;171-176.
18. 2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Mol Pharmacol. 50:1996;34-42.
19. 2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J Biol Chem. 271:1996;14672-14675.
20. Anden N.E., Corrodi H., Fuxe K., Hokfelt T. Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Br J Pharmacol. 34:1968;1-7.
21. Anden N.E., Corrodi H., Fuxe K. Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons. J Pharmacol Exp Ther. 179:1971;236-249.
22. Anden N.E., Corrodi H., Fuxe K., Meek J.L. Hallucinogenic phenylethylamines: interactions with serotonin turnover and receptors. Eur J Pharmacol. 25:1974;176-184.
23. Anderson G.M. III, Braun G., Braun U., Nichols D.E., Shulgin A.T. Absolute configuration and psychotomimetic activity. NIDA Res Monogr. 1978;8-15.
24. Angrist B., Rotrosen J., Gershon S. Assessment of tolerance to the hallucinogenic effects of DOM. Psychopharmacologia. 36:1974;203-207.
25. 2+ channel blockade prevents lysergic acid diethylamide-induced changes in dopamine and serotonin metabolism. Eur J Pharmacol. 332:1997;9-14.
26. Aoki C., Miko I., Oviedo H., Mikeladze-Dvali T., Alexandre L., Sweeney N., Bredt D.S. Electron microscopic immunocytochemical detection of PSD-95, PSD-93, SAP-102, and SAP-97 at postsynaptic, presynaptic, and nonsynaptic sites of adult and neonatal rat visual cortex. Synapse. 40:2001;239-257.
27. Appel J.B., Freedman D.X. Tolerance and cross-tolerance among psychotomimetic drugs. Psychopharmacologia. 13:1968;267-274.
28. Araneda R., Andrade R. 5-hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 40:1991;399-412.
29. 2 agonist DOI. Eur J Pharmacol. 161:1989;45-51.
30. 2A,2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci. 11:1999;2917-2934.
31. 2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex. Eur J Neurosci. 11:1999;3064-3072.
32. Asanuma C. Noradrenergic innervation of the thalamic reticular nucleus: a light and electron microscopic immunohistochemical study in rats. J Comp Neurol. 319:1992;299-311.
33. 2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse. 17:1994;173-181.
34. Aston-Jones G., Bloom F.E. Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J Neurosci. 1:1981;887-900.
35. Aulakh C.S., Mazzola-Pomietto P., Hill J.L., Murphy D.L. Role of various 5-HT receptor subtypes in mediating neuroendocrine effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats. J Pharmacol Exp Ther. 271:1994;143-148.
36. Aulakh C.S., Mazzola-Pomietto P., Wozniak K.M., Hill J.L., Murphy D.L. Evidence that 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane-induced hypophagia and hyperthermia in rats is mediated by serotonin-2A receptors. J Pharmacol Exp Ther. 270:1994;127-132.
37. 1A receptors. Br J Pharmacol. 100:1990;793-799.
38. Balestrieri A., Fontanari D. Acquired and cross tolerance to mescaline, LSD-25, and BOL-148. Arch Gen Psychiatry. 1:1959;279-282.
39. Bankson M.G., Cunningham K.A. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther. 297:2001;846-852.
40. Barfknecht C.F., Nichols D.E. Effects of S-(+)- and R-(-)-3,4, dimethoxyphenylisopropylamines in the rat. J Med Chem. 15:1972;109-110.
41. Barker S.A., Monti J.A., Christian S.T. N,N-dimethyltryptamine: an endogenous hallucinogen. Int Rev Neurobiol. 22:1981;83-110.
42. Barr H.L., Langs R.J., Holt R.R., Goldberger L., Klein G.S. LSD: Personality and Experience. 1972;Wiley-Interscience, New York.
43. Behrendt R.P. Hallucinations: synchronisation of thalamocortical gamma oscillations underconstrained by sensory input. Conscious Cogn. 12:2003;413-451.
44. Beique J.C., Andrade R. PSD-95 regulates synaptic transmission and plasticity in rat cerebral cortex. J Physiol. 546:2003;859-867.
45. Berendsen, H. H. G. (1991). Behavioural consequences of selective activation of 5-HT receptor subtypes; possible implications for the mode of action of antidepressants. Ph.D. dissertation, University of Groningen, The Netherlands.
46. Berendsen H.H., Broekkamp C.L. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol. 101:1990;667-673.
47. Berg K.A., Clarke W.P., Sailstad C., Saltzman A., Maayani S. Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. Mol Pharmacol. 46:1994;477-484.
48. 2C receptor agonists. Ann NY Acad Sci. 861:1998;104-110.
49. Berg K.A., Maayani S., Goldfarb J., Scaramellini C., Leff P., Clarke W.P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 54:1998;94-104.
50. Beyerstein B.L., Dal Cason T.A., Franzosa E.S., Hugel J., Kalchik M., Laing R., Lankin d., Meyers J., Shulgin A.T. Hallucinogens. A Forensic Handbook. 2003;Academic Press, New York.
51. Blair J.B., Kurrasch-Orbaugh D., Marona-Lewicka D., Cumbay M.G., Watts V.J., Barker E.L., Nichols D.E. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 43:2000;4701-4710.
52. Blake R., Logothetis N.K. Visual competition. Nat Rev Neurosci. 3:2002;13-21.
53. 2 receptors and serotonergic axons in rat neocortex. Brain Res. 453:1988;315-328.
54. Boarder M.R. The mode of action of indoleamine and other hallucinogens. Essays Neurochem Neuropharmacol. 2:1977;21-48.
55. Bockaert J., Premont J., Glowinski J., Thierry A.M., Tassin J.P. Topographical distribution of dopaminergic innervation and of dopaminergic receptors in the rat striatum: II. Distribution and characteristics of dopamine adenylate cyclase-interaction of D-LSD with dopaminergic receptors. Brain Res. 107:1976;301-315.
56. 6 receptor. Mol Pharmacol. 52:1997;515-523.
57. 6 receptor. J Neurochem. 71:1998;2169-2177.
58. Braff D.L., Geyer M.A. Acute and chronic LSD effects on rat startle: data supporting an LSD-rat model of schizophrenia. Biol Psychiatry. 15:1980;909-916.
59. 2 receptor. Mol Pharmacol. 38:1990;604-609.
60. Brandrup E., Vanggaard T. LSD treatment in a severe case of compulsive neurosis. Acta Psychiatr Scand. 55:1977;127-141.
61. Brawley P., Duffield J.C. The pharmacology of hallucinogens. Pharmacol Rev. 24:1972;31-66.
62. Brimblecombe R.W. Psychotomimetic drugs: biochemistry and pharmacology. Adv Drug Res. 7:1973;165-206.
63. Brimblecombe R.W., Pinder R.M. Hallucinogenic Agents. 1975;Wright-Scientechnica, Bristol, UK.
64. Brink C.B. Protean behavior by agonists: agonist-directed trafficking of receptor signaling. Trends Pharmacol Sci. 23:2002;454-455.
65. Browne R.G., Ho B.T. Role of serotonin in the discriminative stimulus properties of mescaline. Pharmacol Biochem Behav. 3:1975;429-435.
66. 2 receptor binding in rat brain. Eur J Pharmacol. 109:1985;421-425.
67. 2 receptors. Life Sci. 42:1988;2439-2445.
68. 2 receptors in rat brain. Neuropsychopharmacology. 3:1990;137-148.
69. 2A receptor mRNA in human brain. Brain Res. 676:1995;157-168.
70. Burnet P.W., Chen C.P., McGowan S., Franklin M., Harrison P.J. The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience. 73:1996;531-540.
71. 1C receptor agonist. J Pharmacol Exp Ther. 258:1991;891-896.
72. Burt D.R., Creese I., Snyder S.H. Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Mol Pharmacol. 12:1976;631-638.
73. Callaway J.C., Raymon L.P., Hearn W.L., McKenna D.J., Grob C.S., Brito G.S., Mash D.C. Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. J Anal Toxicol. 20:1996;492-497.
74. Carter O.L., Pettigrew J.D. A common oscillator for perceptual rivalries. Perception. 32:2003;295-305.
75. Carter D., Champney M., Hwang B., Eglen R.M. Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea-pig isolated ileum. Eur J Pharmacol. 280:1995;243-250.
76. Cedarbaum J.M., Aghajanian G.K. Activation of locus coeruleus neurons by peripheral stimuli: modulation by a collateral inhibitory mechanism. Life Sci. 23:1978;1383-1392.
77. Cerletti A., Rothlin E. Role of 5-hydroxytryptamine in mental disease and its antagonism to lysergic acid derivatives. Nature. 176:1955;785-786.
78. Cermakian N., Monaco L., Pando M.P., Dierich A., Sassone-Corsi P. Altered behavioral rhythms and clock gene expression in mice with a targeted mutation in the Period1 gene. EMBO J. 20:2001;3967-3974.
79. 2A receptor derived from an in silico activated G-protein coupled receptor. J Comput Aided Mol Des. 16:2002;511-520.
80. Chambers J.J., Kurrasch-Orbaugh D.M., Parker M.A., Nichols D.E. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. J Med Chem. 44:2001;1003-1010.
81. 2A/2C receptor ligands. J Med Chem. 46:2003;3526-3535.
82. 2 agonist augments gamma-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience. 54:1993;409-420.
83. Chilcoat H.D., Schutz C.G. Age-specific patterns of hallucinogen use in the US population: an analysis using generalized additive models. Drug Alcohol Depend. 43:1996;143-153.
84. Cho K.O., Hunt C.A., Kennedy M.B. The rat brain postsynaptic density fraction contains a homolog of the Drosophila discs-large tumor suppressor protein. Neuron. 9:1992;929-942.
85. Cholden L.S., Kurland A., Savage C. Clinical reactions and tolerance to LSD in chronic schizophrenia. J Nerv Ment Dis. 122:1955;211-221.
86. 2C receptor knockout mouse. Physiol Behav. 78:2003;641-649.
87. Cohen S. Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis. 130:1960;30-40.
88. Cohen S. Psychotomimetic agents. Annu Rev Pharmacol. 7:1967;301-318.
89. Colpaert F.C., Janssen P.A. A characterization of LSD-antagonist effects of pirenperone in the rat. Neuropharmacology. 22:1983;1001-1005.
90. Colpaert F.C., Niemegeers C.J., Janssen P.A. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol Exp Ther. 221:1982;206-214.
91. Commissaris R.L., Lyness W.H., Cordon J.J., Moore K.E., Rech R.H. Behavioral tolerance to the effects of LSD in the rat. Subst Alcohol Actions Misuse. 1:1980;203-207.
92. Conn P.J., Sanders-Bush E. Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology. 23:1984;993-996.
93. Conn P.J., Sanders-Bush E. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J Neurosci. 6:1986;3669-3675.
94. Corbett L., Christian S.T., Morin R.D., Benington F., Smythies J.R. Hallucinogenic N-methylated indolealkylamines in the cerebrospinal fluid of psychiatric and control populations. Br J Psychiatry. 132:1978;139-144.
95. 2A receptor in the central nervous system of adult rat. J Comp Neurol. 409:1999;187-209.
96. Creese I., Burt D.R., Synder S.H. The dopamine receptor: differential binding of D-LSD and related agents to agonist and antagonist states. Life Sci. 17:1975;1715-1719.
97. Crick F. Function of the thalamic reticular complex: the searchlight hypothesis. Proc Natl Acad Sci USA. 81:1984;4586-4590.
98. Cunningham K.A., Appel J.B. Neuropharmacological reassessment of the discriminative stimulus properties of D-lysergic acid diethylamide (LSD). Psychopharmacology (Berl). 91:1987;67-73.
99. i(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol. 62:2002;578-589.
100. Cyr M., Landry M., Di Paolo T. Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology. 23:2000;69-78.
101. Dall'Olio R., Gaggi R., Bonfante V., Gandolfi O. The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol. 10:1999;63-71.
102. 2 receptors? Pharmacol Biochem Behav. 36:1990;901-906.
103. 2 receptors induces glycogenolysis in the rat brain. Eur J Pharmacol. 464:2003;135-140.
104. Davies M.F., Deisz R.A., Prince D.A., Peroutka S.J. Two distinct effects of 5-hydroxytryptamine on single cortical neurons. Brain Res. 423:1987;347-352.
105. Davis M., Sheard M.H. Biphasic dose-response effects of N-N-dimethyltryptamine on the rat startle reflex. Pharmacol Biochem Behav. 2:1974;827-829.
106. Davis M., Cassella J.V., Wrean W.H., Kehne J.H. Serotonin receptor subtype agonists: differential effects on sensorimotor reactivity measured with acoustic startle. Psychopharmacol Bull. 22:1986;837-843.
107. 2A antagonists in psychiatric disorders. Curr Opin Investig Drugs. 3:2002;106-112.
108. de Saint H.Z., Orosco M., Rouch C., Python A., Nicolaidis S. Neuromodulation of the prefrontal cortex during sleep: a microdialysis study in rats. NeuroReport. 11:2000;1619-1624.
109. 1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J Pharmacol Exp Ther. 238:1986;248-253.
110. 2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem. 85:2003;1-13.
111. Delgado P.L., Moreno F.A. Hallucinogens, serotonin and obsessive-compulsive disorder. J Psychoactive Drugs. 30:1998;359-366.
112. 2 receptors. Biochem Pharmacol. 41:1991;1739-1744.
113. deMontigny C., Aghajanian G.K. Preferential action of 5-methoxytryptamine and 5-methoxydimethyltryptamine on presynaptic serotonin receptors: a comparative iontophoretic study with LSD and serotonin. Neuropharmacology. 16:1977;811-818.
114. 3H)lysergic acid diethylamide: cellular autoradiographic localization in rat brain. Science. 173:1971;1022-1024.
115. Diaz J.L. Ethnopharmacology of sacred psychoactive plants used by the Indians of Mexico. Annu Rev Pharmacol Toxicol. 17:1977;647-675.
116. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 31(Suppl 2):1998;80-84.
117. Dixon A.K. Evidence of catecholamine mediation in the "aberrant" behaviour induced by lysergic acid diethylamide (LSD) in the rat. Experientia. 24:1968;743-747.
118. Dobkin D.R. Ayahuasca - the healing vine. Int J Soc Psychiatry. 17:1971;256-269.
119. Doherty M.D., Pickel V.M. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res. 864:2000;176-185.
120. Dragunow M., Currie R.W., Faull R.L., Robertson H.A., Jansen K. Immediate-early genes, kindling and long-term potentiation. Neurosci Biobehav Rev. 13:1989;301-313.
121. Dumuis A., Sebben M., Bockaert J. Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. Mol Pharmacol. 33:1988;178-186.
122. 2A receptor. Methods Enzymol. 343:2002;123-136.
123. 2A receptor determines relative efficacy. Mol Pharmacol. 63:2003;36-43.
124. Edelman G.M. The Remembered Present: A Biological Theory of Consciousness. 1989;Basic Books, New York.
125. Edelman G.M. Naturalizing consciousness: a theoretical framework. Proc Natl Acad Sci USA. 100:2003;5520-5524.
126. 2C receptors. Psychopharmacology (Berl). 136:1998;409-414.
127. 2 receptors. Naunyn-Schmiedeberg's Arch Pharmacol. 325:1984;328-336.
128. Erdtmann-Vourliotis M., Mayer P., Riechert U., Hollt V. Acute injection of drugs with low addictive potential (delta(9)-tetrahydrocannabinol, 3,4-methylenedioxymethamphetamine, lysergic acid diamide) causes a much higher c-fos expression in limbic brain areas than highly addicting drugs (cocaine and morphine). Brain Res Mol Brain Res. 71:1999;313-324.
129. 2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proc Natl Acad Sci USA. 87:1990;2187-2191.
130. 2C receptors in the stimulus effects of hallucinogenic drugs: III. The mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion. Psychopharmacology (Berl). 121:1995;364-372.
131. 2C receptors in the stimulus effects of hallucinogenic drugs: II. reassessment of LSD false positives. Psychopharmacology (Berl). 121:1995;357-363.
132. 2C receptors in the stimulus effects of hallucinogenic drugs: I. Antagonist correlation analysis. Psychopharmacology (Berl). 121:1995;347-356.
133. Freedman D.X. Effects of LSD-25 on brain serotonin. J Pharmacol Exp Ther. 134:1961;160-166.
134. Freedman D.X. On the use and abuse of LSD. Arch Gen Psychiatry. 18:1968;330-347.
135. Freedman D.X. The psychopharmacology of hallucinogenic agents. Annu Rev Med. 20:1969;409-418.
136. Freedman D.X., Boggan W.O. Brain serotonin metabolism after tolerance dosage of LSD. Adv Biochem Psychopharmacol. 10:1974;151-157.
137. Freedman D.X., Aghajanian G.K., Ornitz E.M., Rosner B.S. Patterns of tolerance to lysergic acid diethylamide and mescaline in rats. Science. 127:1958;1173-1174.
138. Freedman D.X., Gottleib R., Lovell R.A. Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism. Biochem Pharmacol. 19:1970;1181-1188.
139. 2 receptor agonist, on local cerebral glucose metabolism in awake rats. Brain Res. 541:1991;63-69.
140. Fuller D.G. Severe solar maculopathy associated with the use of lysergic acid diethylamide (LSD). Am J Ophthalmol. 81:1976;413-416.
141. Fuxe K., Holmstedt B., Jonsson G. Effects of 5-methoxy-N,N- dimethyltryptamine on central monoamine neurons. Eur J Pharmacol. 19:1972;25-34.
142. Gaddum J.H. Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J Physiol. 121:1953;15.
143. Gaddum J.H., Hameed K.A. Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol. 9:1954;240-248.
144. 2 receptor indicates binding site structure. Med Chem Res. 3:1993;52-66.
145. Gatzke H.D. The effect of lysergic acid diethylamide (LSD) on the rat cortex. A quantitative autoradiographic study. Verh Anat Ges. 1977;163-169.
146. 2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neuroscience. 58:1994;515-525.
147. Gewirtz J.C., Marek G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology. 23:2000;569-576.
148. Geyer M.A. Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry. 31(Suppl 2):1998;73-79.
149. Geyer M.A., Tapson G.S. Habituation of tactile startle is altered by drugs acting on serotonin-2 receptors. Neuropsychopharmacology. 1:1988;135-147.
150. 2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro. Life Sci. 63:1998;215-222.
151. Gillin J.C., Kaplan J., Stillman R., Wyatt R.J. The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. Am J Psychiatry. 133:1976;203-208.
152. Gimpl M.P., Gormezano I., Harvey J.A. Effects of LSD on learning as measured by classical conditioning of the rabbit nictitating membrane response. J Pharmacol Exp Ther. 208:1979;330-334.
153. Ginzel K.H., Mayer-Gross W. Prevention of psychological effects of D-lysergic acid diethylamide (LSD 25) by its 2-brom derivative (BOL 148). Nature. 178:1956;210.
154. Glaser T., Rath M., Traber J., Zilles K., Schleicher A. Autoradiographic identification and topographical analyses of high affinity serotonin receptor subtypes as a target for the novel putative anxiolytic TVX Q 7821. Brain Res. 358:1985;129-136.
155. Glennon R.A. Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships. NIDA Res Monogr. 94:1989;43-67.
156. Glennon R.A. Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol Biochem Behav. 64:1999;251-256.
157. Glennon R.A. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 46:2003;2795-2812.
158. Glennon R.A., Rosecrans J.A., Young R. Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev. 3:1983;289-340.
159. Glennon R.A., Young R., Jacyno J.M. Indolealkylamine and phenalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substituents on behavioral activity. Biochem Pharmacol. 32:1983;1267-1273.
160. 2 antagonists. Eur J Pharmacol. 91:1983;189-196.
161. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35:1984;2505-2511.
162. Glennon R.A., Young R., Hauck A.E., McKenney J.D. Structure-activity studies on amphetamine analogs using drug discrimination methodology. Pharmacol Biochem Behav. 21:1984;895-901.
163. Glennon R.A., Titeler M., Young R. Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol Bull. 22:1986;953-958.
164. Glennon R.A., Titeler M., Lyon R.A. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol Biochem Behav. 30:1988;597-601.
165. Gogerty J.H., Dille J.M. Pharmacology of D-lysergic acid morpholide (LSM). J Pharmacol Exp Ther. 120:1957;340-348.
166. Goldberg E. The Executive Brain. Frontal Lobes and the Civilized Mind. 2001;Oxford University Press, New York.
167. Gomez-Cambronero J., Keire P. Phospholipase D: a novel major player in signal transduction. Cell Signal. 10:1998;387-397.
168. Gonzalez-Maeso J., Yuen T., Ebersole B.J., Wurmbach E., Lira A., Zhou M., Weisstaub N., Hen R., Gingrich J.A., Sealfon S.C. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci. 23:2003;8836-8843.
169. Gormezano I., Kehoe E.J., Marshall B. Twenty years of classical conditioning research with the rabbit. Sprague J.M., Epstein A.N. Progress in Psychobiology and Physiological Psychology. 1983;197-275 Academic Press, New York.
170. Gouzoulis-Mayfrank E., Heekeren K., Thelen B., Lindenblatt H., Kovar K.A., Sass H., Geyer M.A. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol. 9:1998;561-566.
171. Gouzoulis-Mayfrank E., Schneider F., Friedrich J., Spitzer M., Thelen B., Sass H. Methodological issues of human experimental research with hallucinogens. Pharmacopsychiatry. 31(Suppl 2):1998;114-118.
172. 18F]FDG. Neuropsychopharmacology. 20:1999;565-581.
173. Gouzoulis-Mayfrank E., Thelen B., Maier S., Heekeren K., Kovar K.A., Sass H., Spitzer M. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology. 45:2002;205-212.
174. Gray J.A., Roth B.L. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull. 56:2001;441-451.
175. Gray J.A., Sheffler D.J., Bhatnagar A., Woods J.A., Hufeisen S.J., Benovic J.L., Roth B.L. Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic
176. 2A receptor desensitization. Biochemistry. 42:2003;10853-10862.
177. Gresch P.J., Strickland L.V., Sanders-Bush E. Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. Neuroscience. 114:2002;707-713.
178. Grob C.S., McKenna D.J., Callaway J.C., Brito G.S., Neves E.S., Oberlaender G., Saide O.L., Labigalini E., Tacla C., Miranda C.T., Strassman R.J., Boone K.B. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 184:1996;86-94.
179. Grob C.S., Greer G.R., Mangini M. Hallucinogens at the turn of the century: an introduction. J Psychoactive Drugs. 30:1998;315-319.
180. Grof S. Realms of the human unconscious. Observations from LSD Research. 1975;Viking Press, New York.
181. Grof S., Grof C. Beyond Death. The Gates of Consciousness. 1980;Thames and Hudson, London.
182. Grof S., Goodman L.E., Richards W.A., Kurland A.A. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry. 8:1973;129-144.
183. Grof S., Soskin R.A., Richards W.A., Kurland A.A. DPT as an adjunct in psychotherapy of alcoholics. Int Pharmacopsychiatry. 8:1973;104-115.
184. Haigler H.J., Aghajanian G.K. Mescaline and LSD: direct and indirect effects on serotonin-containing neurons in brain. Eur J Pharmacol. 21:1973;53-60.
185. Halpern J.H. The use of hallucinogens in the treatment of addiction. Addict Res. 4:1996;177-189.
186. Halpern J.H. Hallucinogens: an update. Curr Psychiatry Rep. 5:2003;347-354.
187. Halpern J.H., Pope H.G. Jr. Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend. 53:1999;247-256.
188. Halpern J.H., Pope H.G. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 69:2003;109-119.
189. 2A receptor in rat cerebral cortex and olfactory system revealed by immunohistochemistry using two antibodies raised in rabbit and chicken. Brain Res Mol Brain Res. 54:1998;199-211.
190. 1A receptors: pharmacological, biochemical, functional, and regulatory properties. Ann NY Acad Sci. 600:1990;114-129.
191. Hanes K.R. Serotonin, psilocybin, and body dysmorphic disorder: a case report. J Clin Psychopharmacol. 16:1996;188-189.
192. 125I]LSD binding to serotonin and dopamine receptors in bovine caudate membranes. Neurochem Int. 7:1985;699-707.
193. 2 receptors in mouse brain. Life Sci. 37:1985;657-664.
194. 2A receptor in learning. Learn Mem. 10:2003;355-362.
195. Harvey J.A., Gormezano I., Cool V.A. Effects of D-lysergic acid diethylamide, D-2-bromolysergic acid diethylamide, DL-2,5-dimethoxy-4- methylamphetamine and D-amphetamine on classical conditioning of the rabbit nictitating membrane response. J Pharmacol Exp Ther. 221:1982;289-294.
196. Harvey J.A., Gormezano I., Cool-Hauser V.A., Schindler C.W. Effects of LSD on classical conditioning as a function of CS-UCS interval: relationship to reflex facilitation. Pharmacol Biochem Behav. 30:1988;433-441.
197. Hasler F., Bourquin D., Brenneisen R., Bar T., Vollenweider F.X. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 72:1997;175-184.
198. Hasuo H., Matsuoka T., Akasu T. Activation of presynaptic 5-hydroxytryptamine 2A receptors facilitates excitatory synaptic transmission via protein kinase C in the dorsolateral septal nucleus. J Neurosci. 22:2002;7509-7517.
199. Hawks R.L., Chiang C.N. Urine Testing for Drugs of Abuse. 1986;Department of Health and Human Services, Rockville, MD.
200. 1A receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain. Ann NY Acad Sci. 780:1996;193-212.
201. Henderson L.A. LSD use and LSD users: questions and answers about LSD. Henderson L.A., Glass W.J. LSD: Still with Us After All These Years. 1994;77-98 Lexington Books, New York.
202. Hermle L., Funfgeld M., Oepen G., Botsch H., Borchardt D., Gouzoulis E., Fehrenbach R.A., Spitzer M. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry. 32:1992;976-991.
203. Hermle L., Gouzoulis-Mayfrank E., Spitzer M. Blood flow and cerebral laterality in the mescaline model of psychosis. Pharmacopsychiatry. 31(Suppl 2):1998;85-91.
204. Hoffer A. A program for the treatment of alcoholism: LSD, malvaria and nicotinic acid. Abramson H.A. The Use of LSD in Psychotherapy and Alcoholism. 1967;343-406 Bobbs-Merrill, Indianapolis.
205. Hofmann A. How LSD originated. J Psychedelic Drugs. 11:1979;53-60.
206. Hofmann A. Notes and documents concerning the discovery of LSD. 1970. Agents Actions. 43:1994;79-81.
207. Hoffman A.J., Nichols D.E. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J Med Chem. 28:1985;1252-1255.
208. Hoffmeister F. Negative reinforcing properties of some psychotropic drugs in drug-naive rhesus monkeys. J Pharmacol Exp Ther. 192:1975;468-477.
209. Hollister L.E. Psychotomimetic drugs in man. Iversen L.L., Iversen S.D., Snyder S.H. Handbook of Psychopharmacology. 1978;389-424 Plenum, New York.
210. Hollister L.E. Effects of hallucinogens in humans. Jacobs B.L. Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives. 1984;19-33 Raven Press, New York.
211. Horita A. Some biochemical studies on psilocybin and psilocin. J Neuropsychiatry. 4:1963;270.
212. Horita A., Weber L.J. The enzymatic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol. 7:1961;47-54.
213. 1 recognition sites. J Recept Res. 8:1988;59-81.
214. 2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol. 238:1993;291-296.
215. Hungen K.V., Roberts S., Hill D.F. Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain. Brain Res. 94:1975;57-66.
216. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol. 15:1995;4S-10S.
217. 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res. 698:1995;204-208.
218. Isbell H., Belleville R.E., Fraser H.F., Wikler A., Logan C.R. Studies on lysergic acid diethylamide (LSD-25): I. Effects in former morphine addicts and development of tolerance during chronic intoxication. Arch Neurol Psychiat. 76:1956;468-478.
219. Isbell H., Miner E.J., Logan C.R. Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25). Psychopharmacology (Berl). 1:1959;20-28.
220. Isbell H., Wolbach A.E., Wikler A., Miner E.J. Cross tolerance between LSD and psilocybin. Psychopharmacologia (Berl). 2:1961;147-159.
221. 1C-selective antagonist. J Med Chem. 36:1993;2519-2525.
222. 2 receptors in P11 cells. J Pharmacol Exp Ther. 259:1991;423-429.
223. Jacobs B.L. Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives. 1984;Raven Press, New York.
224. Jaffe J.H. Drug addiction and drug abuse. Gilman A.G., Goodman L.S., Rall T.W., Murad F. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 1985;532-581 Macmillan, New York.
225. Jaffe J.H. Drug addiction and drug abuse. Goodman A.G., Rall T.W., Nies A.S., Taylor P. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 1990;522-573 McGraw-Hill, New York.
226. 2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA. 95:1998;735-740.
227. Jansson A., Tinner B., Bancila M., Verge D., Steinbusch H.W., Agnati L.F., Fuxe K. Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain. J Chem Neuroanat. 22:2001;185-203.
228. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225.
229. 3H]dopamine release from superfused rat brain slices. Eur J Pharmacol. 132:1986;269-276.
230. 2 receptor. Eur J Pharmacol. 239:1993;111-118.
231. Johnson M.P., Loncharich R.J., Baez M., Nelson D.L. Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 45:1994;277-286.
232. 2A receptor in the same manner. Brain Res Mol Brain Res. 49:1997;1-6.
233. 2 receptor from a human to a rat pharmacology. FEBS Lett. 307:1992;324-328.
234. Kast E. LSD and the dying patient. Chic Med Sch Q. 26:1966;80-87.
235. Kast E.C. A concept of death. Aaronson B., Osmond H. Psychedelics: The Uses and Implications of Hallucinogenic Drugs. 1970;366-381 Anchor Books, Garden City, NY.
236. Kast E.C., Collins V.J. Lysergic acid diethylamide as an analgesic agent. Anesth Analg. 43:1964;285-291.
237. Kelly P.H. Proceedings: action of LSD on supersensitive mesolimbic dopamine receptors. Br J Pharmacol. 55:1975;291P.
238. Kelly P.H., Iversen L.L. LSD as an agonist at mesolimbic dopamine receptors. Psychopharmacologia. 45:1975;221-224.
239. 2C/2B receptor antagonist. Br J Pharmacol. 111:1994;797-802.
240. Kilts J.D., Connery H.S., Arrington E.G., Lewis M.M., Lawler C.P., Oxford G.S., O'Malley K.L., Todd R.D., Blake B.L., Nichols D.E., Mailman R.B. Functional selectivity of dopamine receptor agonists: II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther. 301:2002;1179-1189.
241. Kim E., Cho K.O., Rothschild A., Sheng M. Heteromultimerization and NMDA receptor-clustering activity of Chapsyn-110, a member of the PSD-95 family of proteins. Neuron. 17:1996;103-113.
242. 2 receptor-mediated behavior, head-twitch response, in mice. Life Sci. 63:1998;2305-2311.
243. 2 receptor-mediated behavior, head-twitch response, in PCPA-treated mice. Arch Pharm Res. 22:1999;113-118.
244. Kistner U., Wenzel B.M., Veh R.W., Cases-Langhoff C., Garner A.M., Appeltauer U., Voss B., Gundelfinger E.D., Garner C.C. SAP90, a rat presynaptic protein related to the product of the Drosophila tumor suppressor gene dlg-A. J Biol Chem. 268:1993;4580-4583.
245. Klodzinska A., Bijak M., Tokarski K., Pilc A. Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav. 73:2002;327-332.
246. Kornau H.C., Schenker L.T., Kennedy M.B., Seeburg P.H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science. 269:1995;1737-1740.
247. Kornau H.C., Seeburg P.H., Kennedy M.B. Interaction of ion channels and receptors with PDZ domain proteins. Curr Opin Neurobiol. 7:1997;368-373.
248. 2C receptors. Neuropsychopharmacology. 18:1998;339-351.
249. Kurland A.A. LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs. 17:1985;279-290.
250. Kurland A.A., Unger S., Shaffer J.W., Savage C. Psychedelic therapy utilizing LSD in the treatment of the alcoholic patient: a preliminary report. Am J Psychiatry. 123:1967;1202-1209.
251. 2 activation: the involvement of MAP kinases. J Neurochem. 86:2003;980-991.
252. 2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther. 304:2003;229-237.
253. Lambe E.K., Aghajanian G.K. The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex. J Neurosci. 21:2001;9955-9963.
254. Leonard B.E. Some effects of the hallucinogenic drug 2,5-dimethoxy-4- methyl amphetamine on the metabolism of biogenic amines in the rat brain. Psychopharmacologia. 32:1973;33-49.
255. Leonard H.L., Rapoport J.L. Relief of obsessive-compulsive symptoms by LSD and psilocin. Am J Psychiatry. 144:1987;1239-1240.
256. 2/1C receptor activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres. Neuroscience. 53:1993;457-463.
257. Lewin L. Phantastica, Narcotic, and Stimulating Drugs. Their Use and Abuse. 1964;Routledge and Kegan Paul, London.
258. Leysen J.E. Serotonin receptor binding sites. Green A.R. Neuropharmacology of Serotonin. 1985;86-87 Oxford University Press, Oxford.
259. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol. 21:1982;301-314.
260. 2 receptors by DOM treatment. Eur J Pharmacol. 163:1989;145-149.
261. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry. 44:1998;1099-1117.
262. Liu C., Calogero A., Ragona G., Adamson E., Mercola D. EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity. Crit Rev Oncog. 7:1996;101-125.
263. Liu R., Jolas T., Aghajanian G. Serotonin 5-HT(2) receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res. 873:2000;34-45.
264. 2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem. 74:2000;693-701.
265. Lucki I., Nobler M.S., Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther. 228:1984;133-139.
266. 2A positive cortical neurons. Brain Res Mol Brain Res. 71:1999;358-363.
267. Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs. 30:1998;381-418.
268. Manning D.R. Measures of efficacy using G proteins as endpoints: differential engagement of G proteins through single receptors. Mol Pharmacol. 62:2002;451-452.
269. 2A receptor antagonist. Eur J Pharmacol. 259:1994;137-141.
270. Marek G.J., Aghajanian G. Serotonergic amplification of apically-derived EPSPs in neocortical pyramidal cells via a persistent sodium current. Soc Neurosci Abstr. 22:1996;525.9.
271. Marek G.J., Aghajanian G.K. Alpha 1B-adrenoceptor-mediated excitation of piriform cortical interneurons. Eur J Pharmacol. 305:1996;95-100.
272. 2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther. 278:1996;1373-1382.
273. Marek G.J., Aghajanian G.K. 5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by mu-opiate receptor activation. Neuroscience. 86:1998;485-497.
274. Marek G.J., Aghajanian G.K. Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Drug Alcohol Depend. 51:1998;189-198.
275. 2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol. 367:1999;197-206.
276. 2A receptor-induced EPSCs in layer V pyramidal cells of prefrontal cortex: block by lesions of the medial thalamus. Soc Neurosci Abstr. 86:1999;438.
277. Marek G.J., Wright R.A., Schoepp D.D., Monn J.A., Aghajanian G.K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther. 292:2000;76-87.
278. Marek G.J., Wright R.A., Gewirtz J.C., Schoepp D.D. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience. 105:2001;379-392.
279. Marini-Bettolo G.B., Chiavarelli S., Bovet D. Synthetic sympatholytic substances of the ergotamine series: I. Nitrogen substituted derivatives of DL-1,2,3,4-tetrahydro-2-naphthylamine-containing amino and amido functional groups. Gazz Chim Ital. 80:1951;281-298.
280. Marona-Lewicka D., Nichols D.E. Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists. Psychopharmacology (Berl). 120:1995;384-391.
281. Marona-Lewicka, D., & Nichols, D. E. (2002). Behavioral alterations in rats following long-term treatment with low doses of LSD. 5th IUPHAR Satellite Meeting on Serotonin 114.
282. Marona-Lewicka D., Rhee G.S., Sprague J.E., Nichols D.E. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav. 53:1996;99-105.
283. 1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology (Berl). 164:2002;93-107.
284. 2 binding sites with those of serotonin autoreceptors which modulate serotonin release. Naunyn-Schmiedeberg's Arch Pharmacol. 321:1982;165-170.
285. Martin-Ruiz R., Puig M.V., Celada P., Shapiro D.A., Roth B.L., Mengod G., Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci. 21:2001;9856-9866.
286. 2A receptors. Psychopharmacology (Berl). 117:1995;193-199.
287. 2 receptor. Biol Psychiatry. 26:1989;297-302.
288. McCormick D.A., Bal T. Sleep and arousal: thalamocortical mechanisms. Annu Rev Neurosci. 20:1997;185-215.
289. McCormick D.A., Feeser H.R. Functional implications of burst firing and single spike activity in lateral geniculate relay neurons. Neuroscience. 39:1990;103-113.
290. McGlothlin W.H., Arnold D.O. LSD revisited. A ten-year follow-up of medical LSD use. Arch Gen Psychiatry. 24:1971;35-49.
291. McGrew L., Chang M.S., Sanders-Bush E. Phospholipase D activation by endogenous 5-hydroxytryptamine 2C receptors is mediated by Galpha13 and pertussis toxin-insensitive Gbetagamma subunits. Mol Pharmacol. 62:2002;1339-1343.
292. 2 receptors in rat brain. Neuropsychopharmacology. 2:1989;81-87.
293. 125I]DOI, a new psychotomimetic radioligand. Brain Res. 476:1989;45-56.
294. McKenna D.J., Saavedra J.M. Autoradiography of LSD and 2,5-dimethoxyphenylisopropylamine psychotomimetics demonstrates regional, specific cross-displacement in the rat brain. Eur J Pharmacol. 142:1987;313-315.
295. McKenna D.J., Towers G.H. Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview. J Psychoactive Drugs. 16:1984;347-358.
296. McKenna D.J., Towers G.H., Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. J Ethnopharmacol. 10:1984;195-223.
297. McKenna D.J., Repke D.B., Lo L., Peroutka S.J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology. 29:1990;193-198.
298. Meehan S.M., Schechter M.D. Conditioned place preference/aversion to fenfluramine in Fawn Hooded and Sprague-Dawley rats. Prog Neuropsychopharmacol Biol Psychiatry. 18:1994;575-584.
299. Meehan S.M., Schechter M.D. LSD produces conditioned place preference in male but not female Fawn Hooded rats. Pharmacol Biochem Behav. 59:1998;105-108.
300. Meert T.F., De Haes P.L.A.J., Vermote P.C.M. The discriminative stimulus properties of LSD: serotonergic and catecholaminergic interactions. Psychopharmacology (Berl). 101:1990;S71(271).
301. Meert T.F., de Haes P., Janssen P.A. Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats. Psychopharmacology (Berl). 97:1989;206-212.
302. 3H]LSD binding by rat brain slices in vitro: the effect of 5-hydroxytryptamine. Eur J Pharmacol. 67:1980;371-382.
303. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Kane J.M. New Developments in the Pharmacologic Treatment of Schizophrenia. 1991;71-95 NIMH Public Health Service, Washington, DC.
304. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:1999;106S-115S.
305. Meltzer H.Y., Fessler R.G., Simonovic M., Doherty J., Fang V.S. Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors. Psychopharmacology (Berl). 54:1977;39-44.
306. Meltzer H.Y., Wiita B., Tricou B.J., Simonovic M., Fang V.S., Manov G. Effects of serotonin precursors and serotonin agonists on plasma hormone levels. Ho B.T., Schoolar J.D., Usdin E. Serotonin in Biological Psychiatry. 1982;71-95 Raven Press, New York.
307. i values. J Pharmacol Exp Ther. 251:1989;238-246.
308. 2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res. 524:1990;139-143.
309. Miner L.H., Schroeter S., Blakely R.D., Sesack S.R. Ultrastructural localization of the serotonin transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to dopamine terminals. J Comp Neurol. 427:2000;220-234.
310. 2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience. 116:2003;107-117.
311. Mitchell R., McCulloch D., Lutz E., Johnson M., MacKenzie C., Fennell M., Fink G., Zhou W., Sealfon S.C. Rhodopsin-family receptors associate with small G proteins to activate phospholipase D. Nature. 392:1998;411-414.
312. Monte A.P., Waldman S.R., Marona-Lewicka D., Wainscott D.B., Nelson D.L., Sanders-Bush E., Nichols D.E. Dihydrobenzofuran analogues of hallucinogens: 4. Mescaline derivatives. J Med Chem. 40:1997;2997-3008.
313. Monte A.P., Marona-Lewicka D., Lewis M.M., Mailman R.B., Wainscott D.B., Nelson D.L., Nichols D.E. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity. J Med Chem. 41:1998;2134-2145.
314. Moore R.Y., Halaris A.E., Jones B.E. Serotonin neurons of the midbrain raphe: ascending projections. J Comp Neurol. 180:1978;417-438.
315. 2A/2C receptor function. Neuroscience. 72:1996;129-139.
316. Moreno F.A., Delgado P.L. Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry. 154:1997;1037-1038.
317. 2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther. 301:2002;1166-1178.
318. Muller B.M., Kistner U., Kindler S., Chung W.J., Kuhlendahl S., Fenster S.D., Lau L.F., Veh R.W., Huganir R.L., Gundelfinger E.D., Garner C.C. SAP102, a novel postsynaptic protein that interacts with NMDA receptor complexes in vivo. Neuron. 17:1996;255-265.
319. 125I]LSD binding sites in rat brain. Neurosci Lett. 49:1984;13-18.
320. 1A receptors in the modulation of the acoustic startle reflex in rats. Psychopharmacology (Berl). 97:1989;507-513.
321. 2C receptors. Neurosci Lett. 177:1994;111-115.
322. 2 receptor: structurally specific differentiation by ergolines and tryptamines. J Pharmacol Exp Ther. 265:1993;1272-1279.
323. 2C receptors. Naunyn-Schmiedeberg's Arch Pharmacol. 359:1999;1-6.
324. Nichols D.E. Structural correlation between apomorphine and LSD: involvement of dopamine as well as serotonin in the actions of hallucinogens. J Theor Biol. 59:1976;167-177.
325. Nichols D.E. Structure-activity relationships of phenethylamine hallucinogens. J Pharm Sci. 70:1981;839-849.
326. Nichols D.E. Hallucinogens. Verderame M. Handbook of CNS Agents and Local Anesthetics. 1986;303-325 CRC Press, Boca Raton.
327. Nichols D.E. Medicinal chemistry and structure-activity relationships. Cho A.K., Segal D.S. Amphetamine and Its Analogs. 1994;3-41 Academic Press, New York.
328. Nichols D.E. Role of serotoninergic neurons and 5-HT receptors in the action of hallucinogens. Baumgarten H.G., Gothert M. Serotoninergic Neurons and 5-HT Receptors in the CNS. 1997;563-585 Springer-Verlag, Berlin.
329. Nichols D.E., Oberlender R. Structure-activity relationships of MDMA-like substances. NIDA Res Monogr. 94:1989;1-29.
330. Nichols D.E., Oberlender R. Structure-activity relationships of MDMA and related compounds: a new class of psychoactive agents? Peroutka S.J. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of The Drug MDMA. 1990;105-131 Kluwer Academic Publishing, Boston.
331. Nichols C.D., Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology. 26:2002;634-642.
332. Nichols D.E., Ilhan M., Long J.P. Comparison of cardiovascular, hyperthermic, and toxic effects of para-methoxyamphetamine (PMA) and 3, 4-methylenedioxyamphetamine (MDA). Arch Int Pharmacodyn Ther. 214:1975;133-140.
333. Nichols D.E., Shulgin A.T., Dyer D.C. Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. Life Sci. 21:1977;569-575.
334. Nichols D.E., Jadhav K.P., Oberlender R.A., Zabik J.E., Bossart J.F., Hamada A., Miller D.D. Synthesis and evaluation of substituted 2-phenylcyclobutylamines as analogues of hallucinogenic phenethylamines: lack of LSD-like biological activity. J Med Chem. 27:1984;1108-1111.
335. Nichols D.E., Schooler D., Yeung M.C., Oberlender R.A., Zabik J.E. Unreliability of the rat stomach fundus as a predictor of hallucinogenic activity in substituted phenethylamines. Life Sci. 35:1984;1343-1348.
336. Nichols D.E., Hoffman A.J., Oberlender R.A., Riggs R.M. Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats. J Med Chem. 29:1986;302-304.
337. Nichols D.E., Oberlender R., McKenna D.J. Stereochemical aspects of hallucinogenesis. Watson R.R. Biochemistry and Physiology of Substance Abuse. 1991;1-39 CRC Press, Boca Raton.
338. Nichols D.E., Snyder S.E., Oberlender R., Johnson M.P., Huang X.M. 2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines. J Med Chem. 34:1991;276-281.
339. 2A/2C agonist. J Med Chem. 37:1994;4346-4351.
340. Nichols D.E., Frescas S., Marona-Lewicka D., Kurrasch-Orbaugh D.M. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N- diethyllysergamide (LSD). J Med Chem. 45:2002;4344-4349.
341. Nichols C.D., Garcia E.E., Sanders-Bush E. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Brain Res Mol Brain Res. 111:2003;182-188.
342. NIDA Monitoring the Future Study. 2002;. http://www.nida.nih.gov.
343. Nieforth K.A. Psychotomimetic phenethylamines. J Pharm Sci. 60:1971;655-665.
344. Nielsen E.B. Discriminative stimulus properties of lysergic acid diethylamide in the monkey. J Pharmacol Exp Ther. 234:1985;244-249.
345. Niethammer M., Kim E., Sheng M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci. 16:1996;2157-2163.
346. Nocjar C., Roth B.L., Pehek E.A. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience. 111:2002;163-176.
347. 3H]Lysergic acid diethylamide (LSD): differential agonist and antagonist binding properties at 5-HT receptor subtypes in rat brain. Neurochem Int. 14:1989;497-504.
348. O'Brien C.P. Drug addiction and drug abuse. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 2001;574-639 McGraw-Hill, New York.
349. O'Leary G., Nargiso J., Weiss R.D. 3,4-Methylenedioxymethamphetamine (MDMA): a review. Curr Psychiatry Rep. 3:2001;477-483.
350. Oepen G., Fuenfgeld M., Harrington A., Hermle L., Botsch H. Right hemisphere involvement in mescaline-induced psychosis. Psychiatry Res. 29:1989;335-336.
351. Ogren S.O., Fuxe K. Intraventricular injections of galanin counteract development of head twitches induced by the 5-HT-2 agonist 1-(2,5- dimethoxyphenyl-4-bromo)-2-aminopropane. Acta Physiol Scand. 136:1989;297-298.
352. Osmond H. A review of the clinical effects of psychotomimetic agents. Ann NY Acad Sci. 66:1957;418-434.
353. Osmond H., Smythies J. Schizophrenia: a new approach. J Ment Sci. 98:1952;309-315.
354. Ott J. Pharmepena-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. J Psychoactive Drugs. 33:2001;403-407.
355. Ott J., Bigwood J. Teonanacatl Hallucinogenic Mushrooms of North America. 1978;Madrona, Seattle, WA.
356. 2 agonist, (±)-1-(2,5-dimethoxy-4- bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis: I. Acute effects on HPA axis activity and corticotropin-releasing factor-containing neurons in the rat brain. J Pharmacol Exp Ther. 256:1991;787-794.
357. 2 agonist, (±)-1-(2,5-dimethoxy-4- bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis: II. Biochemical and physiological evidence for the development of tolerance after chronic administration. J Pharmacol Exp Ther. 256:1991;795-800.
358. 2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology (Berl). 124:1996;107-116.
359. Pahnke, W. N. (1963). Drugs and Mysticism. An Analysis of the Relationship Between Psychedelic Drugs and the Mystical Consciousness. Ph.D. dissertation, Harvard University, Cambridge, UK.
360. Pahnke W.N., Kurland A.A., Goodman L.E., Richards W.A. LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther. 9:1969;144-152.
361. Pahnke W.N., Kurland A.A., Unger S., Savage C., Grof S. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 212:1970;1856-1863.
362. 3H]LSD binding sites in the raphe nuclei of the brainstem. Brain Res. 274:1983;150-155.
363. Parker L.A. LSD produces place preference and flavor avoidance but does not produce flavor aversion in rats. Behav Neurosci. 110:1996;503-508.
364. 2A receptor. J Med Chem. 41:1998;5148-5149.
365. Pazos A., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain: I. Serotonin-1 receptors. Brain Res. 346:1985;205-230.
366. Pazos A., Cortes R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain: II. Serotonin-2 receptors. Brain Res. 346:1985;231-249.
367. Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain: IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience. 21:1987;123-139.
368. Pehek E.A., McFarlane H.G., Maguschak K., Price B., Pluto C.P. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res. 888:2001;51-59.
369. Pei Q., Lewis L., Sprakes M.E., Jones E.J., Grahame-Smith D.G., Zetterstrom T.S. Serotonergic regulation of mRNA expression of Arc, an immediate early gene selectively localized at neuronal dendrites. Neuropharmacology. 39:2000;463-470.
370. Pessia M., Jiang Z.G., North R.A., Johnson S.W. Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res. 654:1994;324-330.
371. 2 receptor-mediated phosphatidylinositol turnover by D-lysergic acid diethylamide. J Pharmacol Exp Ther. 247:1988;918-925.
372. Pierce P.A., Peroutka S.J. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology (Berl). 97:1989;118-122.
373. 2 receptors. Neuropsychopharmacology. 3:1990;503-508.
374. Pieri L., Pieri M., Haefely W. LSD as an agonist of dopamine receptors in the striatum. Nature. 252:1974;586-588.
375. Poling J.S., Karanian J.W., Salem N. Jr., Vicini S. Time- and voltage-dependent block of delayed rectifier potassium channels by docosahexaenoic acid. Mol Pharmacol. 47:1995;381-390.
376. + channels. Neuropharmacology. 35:1996;983-991.
377. 2C receptors. Brain Res Mol Brain Res. 23:1994;163-178.
378. Prada M.D., Saner A., Burkark W.P., Bartholini G., Pletscher A. Lysergic acid diethylamide: evidence for stimulation of cerebral dopamine receptors. Brain Res. 94:1975;67-73.
379. Prange O., Murphy T.H. Modular transport of postsynaptic density-95 clusters and association with stable spine precursors during early development of cortical neurons. J Neurosci. 21:2001;9325-9333.
380. 2A/2C agonist (±)2,5-dimethoxy-4-iodophenyl-2- aminopropane (DOI). Neuropsychopharmacology. 28:2003;244-252.
381. Rabin R.A., Regina M., Doat M., Winter J.C. 5-HT(2A) receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav. 72:2002;29-37.
382. Randic M., Padjen A. Effect of N,N-dimethyltryptamine and D-lysergic acid diethylamide on the release of 5-hydroxyindoles in rat forebrain. Nature. 230:1971;532-533.
383. 2 antagonists. Brain Res. 385:1986;395-400.
384. 2 binding affinity. Eur J Pharmacol. 132:1986;79-82.
385. Regier D.A., Boyd J.H., Burke J.D. Jr., Rae D.S., Myers J.K., Kramer M., Robins L.N., George L.K., Karno M., Locke B.Z. One-month prevalence of mental disorders in the United States. Based on five epidemiologic catchment area sites. Arch Gen Psychiatry. 45:1988;977-986.
386. Resnick O., Krus D.M., Raskin M. Accentuation of the psychological effects of LSD-25 in normal subjects treated with reserpine. Life Sci. 4:1965;1433-1437.
387. Reynolds P.C., Jindrich E.J. A mescaline associated fatality. J Anal Toxicol. 9:1985;183-184.
388. Riba J., Anderer P., Morte A., Urbano G., Jane F., Saletu B., Barbanoj M.J. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol. 53:2002;613-628.
389. Riba J., Valle M., Urbano G., Yritia M., Morte A., Barbanoj M.J. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 306:2003;73-83.
390. 2A receptor. Mol Pharmacol. 64:2003;1239-1250.
391. Rogawski M.A., Aghajanian G.K. Response of central monoaminergic neurons to lisuride: comparison with LSD. Life Sci. 24:1979;1289-1297.
392. Romano A.G., Harvey J.A. MDMA enhances associative and nonassociative learning in the rabbit. Pharmacol Biochem Behav. 47:1994;289-293.
393. Romano A.G., Bormann N.M., Harvey J.A. A unique enhancement of associative learning produced by methylenedioxyamphetamine. Behav Pharmacol. 2:1991;225-231.
394. Rosecrans J.A., Lovell R.A., Freedman D.X. Effects of lysergic acid diethylamide on the metabolism of brain 5-hydroxytryptamine. Biochem Pharmacol. 16:1967;2011-2021.
395. Roth B.L., Nakaki T., Chuang D.M., Costa E. Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover. Neuropharmacology. 23:1984;1223-1225.
396. 3H]ketanserin recognition sites in rat striatum. J Neurochem. 49:1987;1833-1838.
397. 2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther. 275:1995;1638-1646.
398. 2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther. 280:1997;576-583.
399. 2A receptors. Mol Pharmacol. 52:1997;259-266.
400. 2A receptors: molecular biology and mechanisms of regulation. Crit Rev Neurobiol. 12:1998;319-338.
401. Rothlin E. Lysergic acid diethylamide and related substances. Ann NY Acad Sci. 66:1957;668-676.
402. Ruck C.A., Bigwood J., Staples D., Ott J., Wasson R.G. Entheogens. J Psychedelic Drugs. 11:1979;145-146.
403. 2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology (Berl). 98:1989;495-499.
404. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci. 10:1999;59-90.
405. Sanchez-Vives M.V., McCormick D.A. Cellular and network mechanisms of rhythmic recurrent activity in neocortex. Nat Neurosci. 3:2000;1027-1034.
406. 1C receptor agonists: what next? NIDA Res Monogr. 146:1994;203-213.
407. 1C receptor activation by hallucinogenic drugs. Psychopharmacology (Berl). 105:1991;340-346.
408. Sanders-Bush E., Burris K.D., Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther. 246:1988;924-928.
409. Savage C., Jackson D., Terrill J. LSD, transcendence, and the new beginning. J Nerv Ment Dis. 135:1962;425-439.
410. Schatz H., Mendelblatt F. Solar retinopathy from sun-gazing under the influence of LSD. Br J Ophthalmol. 57:1973;270-273.
411. 2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4- methylenedioxymethamphetamine. Eur J Pharmacol. 223:1992;65-74.
412. Schreiber R., Brocco M., Millan M.J. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the "atypical" antipsychotics, clozapine and risperidone. Eur J Pharmacol. 264:1994;99-102.
413. 1A agonists. J Pharmacol Exp Ther. 273:1995;101-112.
414. Schultes R.E., Hofmann A. Plants of the Gods. Origins of Hallucinogenic Use. 1979;Alfred van der Marck Editions, New York.
415. 2A heteroceptors on thalamocortical glutamatergic neurons. J Neurosci. 20:2000;8846-8852.
416. Scruggs J.L., Schmidt D., Deutch A.Y. The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neurosci Lett. 346:2003;137-140.
417. 2A receptor. J Biol Chem. 270:1995;16683-16688.
418. 6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. NeuroReport. 5:1994;2553-2557.
419. Seguela P., Watkins K.C., Descarries L. Ultrastructural relationships of serotonin axon terminals in the cerebral cortex of the adult rat. J Comp Neurol. 289:1989;129-142.
420. Shapiro D.A., Kristiansen K., Kroeze W.K., Roth B.L. Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol. 58:2000;877-886.
421. Shapiro D.A., Kristiansen K., Weiner D.M., Kroeze W.K., Roth B.L. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem. 277:2002;11441-11449.
422. Shaw E., Woolley D.W. Some serotonin-like activities of lysergic acid diethylamide. Science. 124:1956;121.
423. 2-activated interneuron. Brain Res. 506:1990;62-69.
424. Sheng M. Molecular organization of the postsynaptic specialization. Proc Natl Acad Sci USA. 98:2001;7058-7061.
425. Sherman S.M., Guillery R.W. Functional organization of thalamocortical relays. J Neurophysiol. 76:1996;1367-1395.
426. 2 receptors. NIDA Res Monogr. 146:1994;284-297.
427. Shulgin A.T. Mescaline: the chemistry and pharmacology of its analogs. Lloydia. 36:1973;46-58.
428. Shulgin A.T. Psychotomimetic drugs: structure-activity relationships. Iversen L.L., Iversen S.D., Snyder S.H. Handbook of Psychopharmacology. 1978;243-333 Plenum, New York.
429. Shulgin A.T. Profiles of psychedelic drugs. Psilocybin. J Psychedelic Drugs. 12:1980;79.
430. Shulgin A.T. Chemistry of psychotomimetics. Hoffmeister F., Stille G. Handbook of Experimental Pharmacology. 1981;3-29 Springer-Verlag, Heidelberg.
431. Shulgin A., Shulgin A. PIHKAL a Chemical Love Story. 1991;Transform Press, Berkeley, CA.
432. Shulgin A.T., Shulgin A. TIHKAL. The Continuation. 1997;Transform Press, Berkeley, CA.
433. Siegel S., Freedman D.X. Effects of LSD-25 on classical trace conditioning. Pharmacol Biochem Behav. 30:1988;427-431.
434. Siva Sankar D.V. LSD: A Total Study. 1975;PJD Publications, Westbury, NY.
435. 2C receptors. Pharmacol Biochem Behav. 61:1998;323-330.
436. 2C, receptor. Psychopharmacology (Berl). 144:1999;248-254.
437. Smythies J. The functional neuroanatomy of awareness: with a focus on the role of various anatomical systems in the control of intermodal attention. Conscious Cogn. 6:1997;455-481.
438. Smythies J.R., Sykes E.A., Lord C.P. Structure-activity relationship studies on mescaline: II. Tolerance and cross-tolerance between mescaline and its analogues in the rat. Psychopharmacologia. 9:1966;434-446.
439. 1A autoreceptors on serotoninergic neurons in the midbrain raphe nuclei. Eur J Neurosci. 2:1990;1144-1154.
440. Spano P.F., Kumakura K., Tonon G.C., Govoni S., Trabucchi M. LSD and dopamine-sensitive adenylate-cyclase in various rat brain areas. Brain Res. 93:1975;164-167.
441. Spano P.F., Kumakura K., Trabucchi M. Dopamine-sensitive adenylate cyclase in the retina: a point of action for D-LSD. Adv Biochem Psychopharmacol. 15:1976;357-365.
442. Spitzer M., Thimm M., Hermle L., Holzmann P., Kovar K.A., Heimann H., Gouzoulis-Mayfrank E., Kischka U., Schneider F. Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry. 39:1996;1055-1057.
443. 1B agonists. Synapse. 1:1987;3-9.
444. 1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology. 27:1988;707-715.
445. Steinmetz J.E. Brain substrates of classical eyeblink conditioning: a highly localized but also distributed system. Behav Brain Res. 110:2000;13-24.
446. Steriade M., Nunez A., Amzica F. A novel slow (<1 Hz) oscillation of neocortical neurons in vivo: depolarizing and hyperpolarizing components. J Neurosci. 13:1993;3252-3265.
447. Stewart O.C. Peyote Religion. A History. 1987;University of Oklahoma Press, Norman, OK.
448. Strassman R.J. Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis. 172:1984;577-595.
449. Strassman R.J. Human hallucinogenic drug research in the United States: a present-day case history and review of the process. J Psychoactive Drugs. 23:1991;29-38.
450. Strassman R.J. Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects. J Nerv Ment Dis. 183:1995;127-138.
451. Strassman R.J. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res. 73:1996;121-124.
452. Strassman R.J., Qualls C.R. Dose-response study of N,N- dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 51:1994;85-97.
453. Strassman R.J., Qualls C.R., Uhlenhuth E.H., Kellner R. Dose-response study of N,N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 51:1994;98-108.
454. Strassman R.J., Qualls C.R., Berg L.M. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry. 39:1996;784-795.
455. 2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex. Neuroscience. 105:2001;55-69.
456. Szara S. DMT (N,N-dimethyltryptamine) and homologues: clinical and pharmacological considerations. Efron D.H. Psychotomimetic Drugs. 1970;275-286 Raven Press, New York.
457. Szara S., Rockland L.H., Rosenthal D., Handlon J.H. Psychological effects and metabolism of N,N-diethyltryptamine in man. Arch Gen Psychiatry. 15:1966;320-329.
458. Tanaka E., North R.A. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophysiol. 69:1993;1749-1757.
459. Taschner, K. L., & Wanke, K. (1975). Problems of toxic psychosis as illustrated on the example of the so-called LSD psychosis. Fortschr Med 93, 1515-1518, 1542.
460. 2A/2C receptor activation is differentially regulated in four regions of rat brain. Eur J Pharmacol. 307:1996;211-217.
461. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl). 94:1988;213-216.
462. Tomita S., Nicoll R.A., Bredt D.S. PDZ protein interactions regulating glutamate receptor function and plasticity. J Cell Biol. 153:2001;F19-F24.
463. Tononi G., Edelman G.M. Consciousness and the integration of information in the brain. Adv Neurol. 77:1998;245-279.
464. Tournois C., Mutel V., Manivet P., Launay J.M., Kellermann O. Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line. Involvement of arachidonic acid metabolism. J Biol Chem. 273:1998;17498-17503.
465. Tricklebank M.D., Forler C., Middlemiss D.N., Fozard J.R. Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N- dimethyltryptamine in the rat. Eur J Pharmacol. 117:1985;15-24.
466. Trulson M.E., Ross C.A., Jacobs B.L. Lack of tolerance to the depression of raphe unit activity by lysergic acid diethylamide. Neuropharmacology. 16:1977;771-774.
467. Trulson M.E., Heym J., Jacobs B.L. Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats. Brain Res. 215:1981;275-293.
468. Twarog B.M. Serotonin: history of a discovery. Comp Biochem Physiol C. 91:1988;21-24.
469. Twarog B.M., Page I.H. Am J Physiol. 175:1953;157.
470. U'prichard D.C., Greenberg D.A., Snyder S.H. Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors. Mol Pharmacol. 13:1977;454-473.
471. Udenfriend S., Weissback H., Clark C.T. The estimation of 5-hydroxytryptamine (serotonin) in biological tissues. J Biol Chem. 215:1955;337-344.
472. Umbricht D., Vollenweider F.X., Schmid L., Grubel C., Skrabo A., Huber T., Koller R. Effects of the 5-HT(2A) agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 28:2003;170-181.
473. Vardy M.M., Kay S.R. LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry. Arch Gen Psychiatry. 40:1983;877-883.
474. Vollenweider F.X. Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry. 31(Suppl 2):1998;92-103.
475. Vollenweider F.X. Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci. 3:2001;265-279.
476. Vollenweider F.X., Geyer M.A. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull. 56:2001;495-507.
477. 18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol. 7:1997;9-24.
478. Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 16:1997;357-372.
479. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Babler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 9:1998;3897-3902.
480. 11C]raclopride. Neuropsychopharmacology. 20:1999;424-433.
481. Von Hungen K., Roberts S., Hill D.F. LSD as an agonist and antagonist at central dopamine receptors. Nature. 252:1974;588-589.
482. Votava Z., Podvalova I., Semonsky M. Studies on the pharmacology of D-lysergic acid cycloalkylamides. Arch Int Pharmacodyn Ther. 115:1958;114-130.
483. Walker E.A., Yamamoto T., Hollingsworth P.J., Smith C.B., Woods J.H. Discriminative-stimulus effects of quipazine and L-5-hydroxytryptophan in relation to serotonin binding sites in the pigeon. J Pharmacol Exp Ther. 259:1991;772-782.
484. Wallach M.B., Hine B., Gershon S. Cross tolerance or tachyphylaxis among various psychotomimetic agents on cats. Eur J Pharmacol. 29:1974;89-92.
485. Wang C.D., Gallaher T.K., Shih J.C. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. Mol Pharmacol. 43:1993;931-940.
486. Wasson R.G., Ingalls D.H. The soma of the Rig Veda: what was it? J Am Orient Soc. 91:1971;169-187.
487. Wasson R.G., Hofmann A., Ruck C.A.P. The Road to Eleusis. Unveiling the Secret of the Mysteries. 1978;Harcourt Brace Jovanovich, New York.
488. 1 dopamine receptors. Psychopharmacology (Berl). 118:1995;401-409.
489. Weinstein H., Osman R., Mercier G. Jr. Recognition and activation of a 5-HT receptor by hallucinogens and indole derivatives. NIDA Res Monogr. 90:1988;243-255.
490. Weinstein H., Zhang D., Ballesteros J.A. Hallucinogens acting at 5-HT receptors: toward a mechanistic understanding at atomic resolution. NIDA Res Monogr. 146:1994;241-262.
491. Whitaker P.M., Seeman P. Hallucinogen binding to dopamine/neuroleptic receptors. J. Pharm. Pharmacol. 29:1977;506-507.
492. Williams R.L. Mammalian phosphoinositide-specific phospholipase C. Biochim Biophys Acta. 1441:1999;255-267.
493. Williams J.T., Colmers W.F., Pan Z.Z. Voltage- and ligand-activated inwardly rectifying currents in dorsal raphe neurons in vitro. J Neurosci. 8:1988;3499-3506.
494. 2A receptors in working memory. J Neurosci. 22:2002;2843-2854.
495. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther. 282:1997;699-706.
496. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 27:1997;79-82.
497. Wing L.L., Tapson G.S., Geyer M.A. 5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology (Berl). 100:1990;417-425.
498. Winter J.C. Tolerance to a behavioral effect of lysergic acid diethylamide and cross-tolerance to mescaline in the rat: absence of a metabolic component. J Pharmacol Exp Ther. 178:1971;625-630.
499. Winter J.C. Blockade of the stimulus properties of mescaline by a serotonin antagonist. Arch Int Pharmacodyn Ther. 214:1975;250-253.
500. Winter J.C. The stimulus effects of serotonergic hallucinogens in animals. NIDA Res Monogr. 146:1994;157-182.
501. Winter J.C., Rabin R.A. Interactions between serotonergic agonists and antagonists in rats trained with LSD as a discriminative stimulus. Pharmacol Biochem Behav. 30:1988;617-624.
502. Winter J.C., Fiorella D.J., Timineri D.M., Filipink R.A., Helsley S.E., Rabin R.A. Serotonergic receptor subtypes and hallucinogen-induced stimulus control. Pharmacol Biochem Behav. 64:1999;283-293.
503. Winter J.C., Doat M., Rabin R.A. Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia. Life Sci. 68:2000;337-344.
504. 1A receptors. Pharmacol Biochem Behav. 65:2000;75-82.
505. Wise R.A. Drug-activation of brain reward pathways. Drug Alcohol Depend. 51:1998;13-22.
506. Wolbach A.B., Miner E.J., Isbell H. Comparison of psilocin with psilocybin, mescaline, and LSD. Psychopharmacologia (Berl ). 3:1962;219-223.
507. 11C]-methyl)-2-Br-LSD. Synapse. 1:1987;393-398.
508. Woolley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Science. 199:1954;587-588.
509. Woolley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA. 40:1954;228-231.
510. Wright D.E., Seroogy K.B., Lundgren K.H., Davis B.M., Jennes L. Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol. 351:1995;357-373.
511. 2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem. 278:2003;21901-21908.
512. Xu Z.Q., Zhang X., Pieribone V.A., Grillner S., Hokfelt T. Galanin-5-hydroxytryptamine interactions: electrophysiological, immunohistochemical and in situ hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors. Neuroscience. 87:1998;79-94.
513. Yamamoto T., Walker E.A., Woods J.H. Agonist and antagonist properties of serotonergic compounds in pigeons trained to discriminate either quipazine or L-5-hydroxytryptophan. J Pharmacol Exp Ther. 258:1991;999-1007.
514. 2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission. Brain Res Bull. 51:2000;75-81.
515. Yensen R., Di Leo F.B., Rhead J.C., Richards W.A., Soskin R.A., Turek B., Kurland A.A. MDA-assisted psychotherapy with neurotic outpatients: a pilot study. J Nerv Ment Dis. 163:1976;233-245.
516. Yocca F.D., Wright R.N., Margraf R.R., Eison A.S. 8-OH-DPAT and buspirone analogs inhibit the ketanserin-sensitive quipazine-induced head shake response in rats. Pharmacol Biochem Behav. 35:1990;251-254.
517. Yritia M., Riba J., Ortuno J., Ramirez A., Castillo A., Alfaro Y., de la T.R., Barbanoj M.J. Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of ayahuasca. J Chromatogr B Analyt Technol Biomed Life Sci. 779:2002;271-281.
518. Zhai Y., George C.A., Zhai J., Nisenbaum E.S., Johnson M.P., Nisenbaum L.K. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology. 28:2003;45-52.
519. Zhou F.M., Hablitz J.J. Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. J Neurophysiol. 82:1999;2989-2999.
520. Zoli M., Torri C., Ferrari R., Jansson A., Zini I., Fuxe K., Agnati L.F. The emergence of the volume transmission concept. Brain Res Brain Res Rev. 26:1998;136-147.